BioIntelliSense Teams up with UAE-based Mubadala Health on Remote Patient Monitoring

BioSticker and BioButton wearable devices to be used for Mubadala's long-term care services.

MDDI Staff

March 9, 2022

2 Min Read
BioIntellisense sticker remote patient monitoring
Image courtesy of BioIntelliSense

Remote patient monitoring devices from BioIntelliSense Inc. are slated for long-term care use by Abu Dhabi, UAE-based Mubadala Health, an integrated healthcare network including Cleveland Clinic Abu Dhabi, Healthpoint, Imperial College London Diabetes Centre (ICLDC), and more. Mubadala Health’s continuous care model aims for clinical workflow efficiencies, data-driven clinical insights, and personalized care experiences.

“The collaboration with Mubadala Health in launching a continuous remote monitoring capability will help providers deliver a new level of care to patients in UAE,” explained James Mault, MD, founder and chief executive officer of BioIntelliSense, in a news release. “This partnership with Mubadala Health represents a tremendous opportunity to apply the BioSticker and BioButton wearable medical devices across multiple care settings, make early detection simple, and empower care teams with personalized clinical intelligence that enables informed proactive interventions.”

Mubadala Health plans to use BioSticker and BioButton wearable devices, along with its algorithmic-based data services, for continuously tracking resting heart rate, respiratory rate, temperature, body position, activity level, sleep, gait analysis, and more. BioCloud analytics and intelligent alerting could also be used to remotely monitor at-risk, long-term care patient populations through a centralized command center using the data from the BioIntelliSense multi-parameter wearable devices, according to the release.

BioSticker was identified early during the pandemic as a potential remote-monitoring solution for COVID-19 patients, and UCLA Health announced in December 2020 that it would employ BioButton when developing a scalable post-vaccine monitoring program.

Mubadala Health is also partnering with BioIntelliSense on similar remote monitoring programs for orthopedics, oncology, end-stage renal disease, post-hospital discharge, home healthcare, and elderly primary care. These programs are facilitated through Tamouh Health, BioIntelliSense’s strategic distribution partner in the UAE, according to the release.

“This partnership is in line with our comprehensive strategy to provide innovative care to our patients and create efficiencies in the way healthcare is delivered,” said Hasan Jasem Al Nowais, chief executive officer of Mubadala Health, in the release. “Through the use of this new technology, Mubadala Health can better meet the needs of patients, delivering customized care, at the right time and place, across our integrated network. BioIntelliSense’s technology will allow our clinicians to access near real-time information on patients’ vital signs and symptoms, enabling them to identify changes in health sooner and intervene earlier.”

“This strategic partnership will help create fully integrated, continuous care delivery that starts during a patient’s hospitalization, enabling monitoring of their health status throughout their recovery process, and from the comfort of their own home after leaving the hospital,” Al Nowais added.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like